RxDoctor Payments Data

Karen Burke, APRN

Adult Health · Columbia, SCNPI 1053680405

Payments from drug & device makers

$1,807in general payments, 2019–2025

Across 101 payments — averaging $17.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$512
  • Bayer$190
  • Lilly USA, LLC$154
  • Novo Nordisk$137
  • GSK$85
  • Boston Scientific$74
  • plus $654 from 19 others

What the payments were for

  • Food & beverage$1,807100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,807 in reported general payments places this provider in the 65th percentile of 292 adult health providers in South Carolina.

See all adult health providers in South Carolina

Medicare billing

Part B allowed, 2024
$149,795
Medicare patients
187
Services billed
1,769

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban81$41,712
FarxigaDapagliflozin Propanediol14$11,303
JardianceEmpagliflozin12$9,891
MyrbetriqMirabegron17$5,166
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$4,764
Lorazepam70$2,634
Quetiapine Fumarate75$2,504
Pantoprazole Sodium56$2,470
Trazodone Hcl96$2,202
Mirtazapine37$1,790
Duloxetine Hcl30$1,370
Donepezil Hcl86$1,360
Losartan Potassium85$1,282
Potassium Chloride46$1,272
Levothyroxine Sodium105$1,208

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$73$41,71281 claims
AstraZenecaFarxiga$12$11,30314 claims
Boehringer IngelheimJardiance$17$9,89112 claims
GSKAnoro Ellipta$85$4,76412 claims
Lilly USA, LLCOlanzapine$154$59924 claims
Teva Pharmaceuticals USA, Inc.Albuterol Sulfate$29$51418 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 292 adult health providers in South Carolina.

Other adult health in Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →